Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 3/20 | 0.56 |
| ▸ | KDR | P35968 | 16/20 | 0.51 |
| ▸ | FLT3 | P36888 | 15/20 | 0.51 |
| ▸ | KIT | P10721 | 13/20 | 0.51 |
| ▸ | CSF1R | P07333 | 6/20 | 0.50 |
| ▸ | FLT4 | P35916 | 6/20 | 0.50 |
| ▸ | LYN | P07948 | 5/20 | 0.50 |
| ▸ | FLT1 | P17948 | 5/20 | 0.50 |
| ▸ | AURKA | O14965 | 4/20 | 0.50 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.50 |
| ▸ | SRC | P12931 | 4/20 | 0.50 |
| ▸ | BLK | P51451 | 4/20 | 0.50 |
| ▸ | CDK19 | Q9BWU1 | 3/20 | 0.50 |
| ▸ | PLK4 | O00444 | 3/20 | 0.50 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.50 |
| ▸ | CDK1 | P06493 | 3/20 | 0.50 |
| ▸ | MET | P08581 | 3/20 | 0.50 |
| ▸ | PRKACA | P17612 | 3/20 | 0.50 |
| ▸ | RPS6KB1 | P23443 | 3/20 | 0.50 |
| ▸ | CSNK1D | P48730 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2819263 | 0.87 | KDR (0.63) | RIPK1KDRFLT3KITCSF1R | |
| SCHEMBL2822262 | 0.85 | KDR (0.58) | RIPK1KDRFLT3KITCSF1R | |
| SCHEMBL2819232 | 0.84 | KIT (0.54) | RIPK1KDRFLT3KITCSF1R | |
| SCHEMBL2816153 | 0.84 | KDR (0.68) | RIPK1KDRFLT3KITCSF1R | |
| SCHEMBL2819450 | 0.84 | KDR (0.57) | RIPK1KDRFLT3KITCSF1R | |
| SCHEMBL2819335 | 0.84 | KDR (0.65) | RIPK1KDRFLT3KITCSF1R | |
| SCHEMBL2819602 | 0.84 | KDR (0.64) | RIPK1KDRFLT3KITCSF1R | |
| SCHEMBL2816436 | 0.84 | KDR (0.67) | RIPK1KDRFLT3KITCSF1R | |
| SCHEMBL2819284 | 0.84 | KDR (0.58) | RIPK1KDRFLT3KITCSF1R | |
| SCHEMBL2819299 | 0.83 | KDR (0.58) | RIPK1KDRFLT3KITCSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7842809-B2 | Pyrazolopyridines and salts thereof, a pharmaceutical composition comprising said compounds, a method of preparing same and use of same | BAYER SCHERING PHARMA AG (DE) | 2010-11-30 | — | — | US | claimed |
| EP-1841767-A1 | PYRAZOLOPYRIDINES, THEIR PREPARATION AND THEIR MEDICAL USE | Bayer Schering Pharma AG (DE) | 2007-10-10 | — | — | EP | claimed |
| US-20060252754-A1 | Pyrazolopyridines and salts thereof, a pharmaceutical composition comprising said compounds, a method of preparing same and use of same | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2006-11-09 | — | — | US | claimed |
| WO-2006077168-A1 | PYRAZOLOPYRIDINES, THEIR PREPARATION AND THEIR MEDICAL USE | BAYER SCHERING PHARMA AG. (DE) | 2006-07-27 | — | — | WO | claimed |
| EP-2061790-B1 | Substituted aminopyrazolopyridines and salts thereof, their preparations and pharmaceutical compositions comprising them | BAYER IP GMBH (DE) | 2014-08-13 | — | — | EP | disclosed |
| US-7846928-B2 | Substituted pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same | BAYER SCHERING PHARMA AG (DE) | 2010-12-07 | — | — | US | disclosed |
| US-7846928-B2 | Substituted pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same | BAYER SCHERING PHARMA AG (DE) | 2010-12-07 | — | — | US | disclosed |
| US-7846928-B2 | Substituted pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same | BAYER SCHERING PHARMA AG (DE) | 2010-12-07 | — | — | US | disclosed |
| US-7842809-B2 | Pyrazolopyridines and salts thereof, a pharmaceutical composition comprising said compounds, a method of preparing same and use of same | BAYER SCHERING PHARMA AG (DE) | 2010-11-30 | — | — | US | disclosed |
| US-7842809-B2 | Pyrazolopyridines and salts thereof, a pharmaceutical composition comprising said compounds, a method of preparing same and use of same | BAYER SCHERING PHARMA AG (DE) | 2010-11-30 | — | — | US | disclosed |
| US-7842809-B2 | Pyrazolopyridines and salts thereof, a pharmaceutical composition comprising said compounds, a method of preparing same and use of same | BAYER SCHERING PHARMA AG (DE) | 2010-11-30 | — | — | US | disclosed |
| US-20080058326-A1 | SUBSTITUTED PYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2008-03-06 | — | — | US | disclosed |
| US-20080058326-A1 | SUBSTITUTED PYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2008-03-06 | — | — | US | disclosed |
| US-20080058326-A1 | SUBSTITUTED PYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2008-03-06 | — | — | US | disclosed |
| EP-1867648-A1 | Substituted aminopyrazolopyridines and salts thereof, their preparations and pharmaceutical compositions comprising them. | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-12-19 | — | — | EP | disclosed |
| EP-1841767-A1 | PYRAZOLOPYRIDINES, THEIR PREPARATION AND THEIR MEDICAL USE | Bayer Schering Pharma AG (DE) | 2007-10-10 | — | — | EP | disclosed |
| US-20060252754-A1 | Pyrazolopyridines and salts thereof, a pharmaceutical composition comprising said compounds, a method of preparing same and use of same | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2006-11-09 | — | — | US | disclosed |
| WO-2006077168-A1 | PYRAZOLOPYRIDINES, THEIR PREPARATION AND THEIR MEDICAL USE | BAYER SCHERING PHARMA AG. (DE) | 2006-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058326-A1 | SUBSTITUTED PYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | KDR, TIE1, FLT1 | RIPK1 2485/4885KDR 1/4885FLT3 39/4885 |
| US-20060252754-A1 | Pyrazolopyridines and salts thereof, a pharmaceutical composition comprising said compounds, a method of preparing same and use of same | TEK, TIE1, KDR | RIPK1 1819/4885KDR 3/4885FLT3 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.